Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer.

@article{Bottomley2008SymptomAQ,
  title={Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer.},
  author={Andrew Bottomley and Channa Debruyne and E Felip and Michael Millward and Luc Thiberville and Giannicola D'addario and Lisa S Rome and Petr Zatloukal and Corneel Coens and Guiseppe Giaccone},
  journal={European journal of cancer},
  year={2008},
  volume={44 15},
  pages={2178-84}
}
AIMS This study reports the symptom and HRQOL results in which standard treatment was compared to standard therapy plus Bec2, an anti-idiotypic antibody that mimics GD3, a ganglioside antigen. METHODS Five hundred and fifteen LD SCLC patients were randomised to receive five vaccinations of Bec2 (2.5mg)/BCG vaccine arm (VA) or an observational arm (OA) administered over a 10-week period. Survival was the primary end-point; HRQOL was a secondary end-point, assessed using the EORTC QLQ-C30/LC 13… CONTINUE READING
10 Citations
10 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 10 references

EORTC QLQ-C30 reference values. EORTC Quality of Life Group, EORTC

  • NW Scott, PM Fayers, NK Aaronson
  • 2008
1 Excerpt

EORTC QLQC 30 reference values

  • NW Scott, PM Fayers, NK Aaronson
  • EORTC Quality of Life Group
  • 2008

EORTC QLQ-C30 scoring manual

  • P Fayers, N Aaronson, K Bjordal, M Groenvold, D Curran, A. Bottomley
  • 2001

Similar Papers

Loading similar papers…